ABT · 10-Q · 2026Q3

ABBOTT LABORATORIES

Filed 2026-11-04 · Healthcare · View original filing on EDGAR

Ranked Events

• Liquidity and Cash PositionImportance 91 · Surprise 88
  At September 30, 2026, cash and cash equivalents were $4.052 billion, down from $8.522 billion at December 31, 2025. Long-term debt was $29.451 billion and current debt was $1.708 billion, compared with $9.896 billion…
• Interest Expense IncreaseImportance 76 · Surprise 82
  Net interest expense increased $253 million to $297 million in the third quarter of 2026. For the first nine months, it increased $521 million to $664 million. The increases primarily reflected interest on debt…
• Exact Sciences AcquisitionImportance 71 · Surprise 60
  Abbott completed its acquisition of Exact Sciences on March 23, 2026, for approximately $20.6 billion, paying $105 per common share in cash. Abbott funded the purchase primarily with $20.0 billion of long-term debt…
• Revenue Performance and MixImportance 64 · Surprise 56
  Third-quarter 2026 net sales rose 14.5% year over year to $13.013 billion, or 14.8% excluding foreign exchange; nine-month sales rose 11.9% to $36.770 billion, or 10.5% excluding foreign exchange. In the first nine…
• Operating Expense TrendsImportance 58 · Surprise 56
  Third-quarter research and development expense rose 17% to $2.579 billion from $2.207 billion. Third-quarter selling, general, and administrative expense increased 40% to $4.266 billion from $3.051 billion. For the…
• Operating Income and MarginsImportance 58 · Surprise 56
  Third-quarter operating earnings fell 34% to $1.358 billion from $2.057 billion, while nine-month operating earnings declined 24% to $4.396 billion from $5.802 billion. Third-quarter net sales grew 14% to $13.013…
• Geographic Market CommentaryImportance 48 · Surprise 40
  For the first nine months of 2026, total U.S. sales increased 17.7%, while total international sales increased 5.9% excluding foreign exchange. In Core Laboratory, diagnostic test sales on the Alinity platform…
• Operating Cash Flow and CapexImportance 48 · Surprise 40
  Net cash from operating activities totaled $5.5 billion in the first nine months of 2026, approximately $700 million below the prior-year period. The decline primarily reflected legal-settlement payments, higher…
• Research and Development InvestmentImportance 47 · Surprise 48
  R&D expense increased $154 million, or 20.1%, to $920 million in the third quarter of 2026. For the first nine months, R&D expense rose $372 million, or 16.9%, to $2.6 billion. The increases primarily reflected the…
• DOJ Infant Formula InvestigationImportance 47 · Surprise 60
  Abbott resolved investigations by the U.S. Department of Justice and complaints in September 2026 concerning its U.S. manufacturing of powdered infant formula. The DOJ and several states had partially intervened in a…
• Income Tax Rate ChangesImportance 42 · Surprise 40
  First-nine-month 2026 taxes on earnings included approximately $540 million of expense related to a deferred tax asset recognized as a significant non-cash tax benefit in a prior year, compared with approximately $460…
• Strategic Business SeparationImportance 41 · Surprise 60
  In October 2026, Abbott announced plans to separate its Nutrition business into an independent, publicly traded company that would include the Nutritional Products segment and brands such as Similac, PediaSure,…
• Infant Formula LitigationImportance 40 · Surprise 42
  Abbott faces lawsuits alleging that cow’s-milk-containing preterm infant formula and human milk fortifier caused necrotizing enterocolitis (NEC) and failed to warn of the risk. In September 2026, Abbott reached…
• Order Backlog and Book-to-BillImportance 38 · Surprise 24
  As of September 30, 2026, Abbott reported approximately $6.2 billion of estimated future revenue from unsatisfied or partially unsatisfied performance obligations in its Diagnostic Products segment. These obligations…
• EP and Rhythm Management GrowthImportance 36 · Surprise 40
  For the first nine months of 2026, Electrophysiology sales increased 13.8% excluding foreign exchange, primarily reflecting increased sales of ablation catheters and related portfolio products. Rhythm Management sales…
• Product Launch and TransitionImportance 31 · Surprise 42
  Abbott received several significant product approvals and launched new products in 2026. Libre Duo, a dual glucose-ketone biowearable sensor, received CE Mark and FDA approval, while the Amulet 360 left atrial…
• Gross Margin DriversImportance 31 · Surprise 32
  Gross profit margin was 50.3% in the third quarter and 51.7% in the first nine months of 2026, versus 51.7% and 52.4%, respectively, in 2025. The decline primarily reflected higher intangible amortization following the…
• Emerging Market Pharmaceutical GrowthImportance 30 · Surprise 40
  Established Pharmaceutical Products sales in Key Emerging Markets increased 10.4% excluding foreign exchange in the first nine months of 2026. Growth was led by double-digit increases in several countries across Latin…
• Capital Return ProgramImportance 24 · Surprise 14
  Abbott paid $3.294 billion of dividends in the first nine months of 2026, compared with $3.086 billion in the same period of 2025. Dividends declared for the nine-month period were $1.89 per common share, up from $1.77…
• Malaysian Tax Assessment AppealImportance 20 · Surprise 24
  In July 2024, Abbott received a tax assessment from Malaysian tax authorities for the 2023 tax year, applying a property capital gains tax to the value of shares associated with an intercompany affiliate sale. The…

Revenue by Product (in millions)

Revenue by Geography (in millions)